Drug Type Chemical drugs |
Synonyms SQ2270 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Neoplasms | Preclinical | United States | 17 Apr 2023 | |
| Non-Hodgkin Lymphoma | Preclinical | United States | 17 Apr 2023 | |
| Stomach Cancer | Preclinical | United States | 17 Apr 2023 |





